The Renin-Angiotensin System (RAS): Mechanisms, Functions and Clinical Significance

The Renin-Angiotensin System (RAS), also commonly referred to as the Renin-Angiotensin-Aldosterone System (RAAS), is one of the most vital hormonal regulatory systems in the human body. It is primarily responsible for maintaining blood pressure stability, balancing water and electrolyte homeostasis, and regulating renal function. For decades, researchers have continuously explored its physiological mechanisms and pathological roles, proving that the dysfunction of the RAS is closely linked to a variety of cardiovascular and renal diseases, making it a core target for modern clinical drug development .

The RAS operates through a precise cascade of enzymatic reactions involving multiple key components, including renin, angiotensinogen, angiotensin I (Ang I), angiotensin II (Ang II), angiotensin-converting enzyme (ACE), and aldosterone. The entire regulatory process starts with specific stimuli such as reduced renal perfusion pressure, decreased sodium concentration in renal tubules, or enhanced sympathetic nerve excitation . Under these conditions, the juxtaglomerular cells in the renal afferent arterioles secrete renin, an aspartyl protease that acts as the rate-limiting enzyme of the entire RAS pathway .

Renin enters the bloodstream and specifically cleaves angiotensinogen, a passive glycoprotein synthesized and secreted by the liver, to generate inactive decapeptide Ang I. Ang I itself has almost no biological activity and serves only as a precursor. Subsequently, ACE, which is abundantly distributed on the surface of vascular endothelial cells, especially in pulmonary and renal blood vessels, catalyzes the hydrolysis of Ang I to produce Ang II, the most functionally active effector peptide of the RAS . Ang II exerts powerful physiological effects by binding to specific G-protein-coupled receptors (mainly AT1 receptors) on target cells.

The core physiological functions of Ang II cover multiple systems of the body. First, it induces strong vasoconstriction of systemic arterioles, increasing peripheral vascular resistance and thereby elevating arterial blood pressure rapidly. Second, it stimulates the zona glomerulosa of the adrenal cortex to secrete aldosterone, which promotes renal reabsorption of sodium and water and accelerates potassium excretion, expanding blood volume and further stabilizing blood pressure and fluid balance . In addition, Ang II can activate the sympathetic nervous system, promote catecholamine release, and enhance cardiac contractility, forming a synergistic regulatory loop for cardiovascular function .

Beyond basic physiological regulation, abnormal activation of the RAS is a key driver of multiple chronic diseases. Excessive accumulation of Ang II leads to persistent vasoconstriction, sodium and water retention, and ultimately essential hypertension. Long-term RAS overactivation also triggers pathological remodeling of the heart and blood vessels, causing myocardial hypertrophy, heart failure, and vascular atherosclerosis . Moreover, sustained high levels of Ang II damage renal endothelial cells, accelerate glomerular fibrosis, and contribute to the progression of chronic kidney disease and diabetic nephropathy .

In clinical medicine, the in-depth understanding of the RAS has revolutionized the treatment of cardiovascular and renal disorders. A series of targeted RAS inhibitors have become first-line therapeutic drugs, including ACE inhibitors (ACEIs) that block Ang II synthesis, angiotensin II receptor blockers (ARBs) that competitively inhibit Ang II binding to receptors, and aldosterone antagonists . These drugs effectively reduce blood pressure, reverse target organ damage, and significantly lower the mortality rate of heart failure and chronic kidney disease, bringing huge clinical benefits to patients.

In recent years, emerging studies have updated the traditional cognition of the RAS. Researchers have discovered a counter-regulatory RAS pathway composed of angiotensin-converting enzyme 2 (ACE2), Ang (1-7) and Mas receptors, which antagonizes the vasoconstrictive and pro-inflammatory effects of the classical RAS, exerting vasodilatory, anti-fibrotic and protective effects on organs . This new finding expands the regulatory network of the RAS and provides new directions for the development of novel targeted drugs.

In conclusion, the RAS is a sophisticated and multi-dimensional regulatory system that maintains human homeostasis under physiological conditions, while its dysregulation is a core pathological mechanism of multiple chronic diseases. Continuous exploration of its molecular mechanisms and regulatory pathways will further optimize clinical treatment strategies and promote the development of precision medicine for cardiovascular and renal diseases.